Clinical trials: Cancer (Solid Tumors)
Neoplasms by Histologic Type
A Trial In Patients With Advanced Cancer And Leukemia
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia
- Trial name
- NCT00878189
- Testing
- PF-03084014
- Where
- 10 sites in United States, Italy
- Volunteers
- 72 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Neoplasms
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
- Trial name
- NCT00207090
- Testing
- ixabepilone, Rifampin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- R-Pharm
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Solid Tumors, Lymphoma
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary…
- Trial name
- NCT02503423
- Testing
- ASTX660
- Where
- 68 sites in United States, Belgium and 6 more
- Volunteers
- 253 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumor
First in Human Study of T3P-Y058-739 (T3P)
This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with…
- Trial name
- NCT05120596
- Testing
- Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT)
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 100 people
- Sponsor
- T3 Pharmaceuticals AG
Select Advanced Solid Tumors
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.
- Trial name
- NCT02705482
- Testing
- MEDI0562, Tremelimumab, Durvalumab
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 58 people
- Sponsor
- MedImmune LLC
Malignant Solid Tumor
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
- Trial name
- NCT07136142
- Testing
- FH-006 for Injection, SHR-1316 Injection, Paclitaxel for Injection (Albumin-Bound)
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Bone Metastasis From Solid Tumors
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
A randomized, double-blind and parallel group study to compare the pharmacokinetic, pharmacodynamic, safety and immunogenicity of HS-20090 120mg（1.7ml）and Xgeva® in healthy adults.
- Trial name
- NCT04494373
- Testing
- HS-20090, Xgeva®
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Phase 1/2 Study to Evaluate MEDI4736
This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in participants with advanced solid tumors followed by an expansion phase in participants with advanced solid tumors.
- Trial name
- NCT01693562
- Testing
- MEDI4736
- Where
- 79 sites in United States, Belgium and 7 more
- Volunteers
- 1,022 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumor
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
- Trial name
- NCT07508761
- Testing
- IPG7236, Toripalimab Injection
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Advanced Solid Tumor
A Study of SHR-A1403 in Patients With Advanced Solid Tumor
SHR-A1403 is a humanized IgG2, anti-C-Met monoclonal antibody conjugated to microtubule inhibitor (c-Met ADC).The aim of this study is to assess the safety and tolerability of SHR-A1403，to define the dose limited toxicity（DLT）and…
- Trial name
- NCT03856541
- Testing
- SHR-A1403
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Advanced Solid Tumors
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer.
- Trial name
- NCT04999202
- Testing
- BAY2416964, Pembrolizumab
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 47 people
- Sponsor
- Bayer
Solid Tumors
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
- Trial name
- NCT03477175
- Testing
- E7080, Comparator Drug, Comparator Drug: Sorafenib
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Advanced Solid Malignancies
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
This study is a single-arm, open-label, multi-centre drug-drug interaction (DDI) study of AZD5305 administered orally in patients with advanced solid tumours.
- Trial name
- NCT05573724
- Testing
- AZD5305, Itraconazole
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Head and Neck Squamous Cell Carcinoma, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232524
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Cancer
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
This study will test whether it is possible to introduce new genetic material into a small portion of a tumor and have the product of the new gene not only kill those tumor cells that were infected initially, but also the…
- Trial name
- NCT01310179
- Testing
- Ad/PNP and fludarabine monophosphate
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- PNP Therapeutics, Inc.
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Advanced Cancer, Metastatic Cancer
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives…
- Conditions
- Advanced Cancer, Metastatic Cancer, Lymphoma, Solid Tumors
- Trial name
- NCT00741403
- Testing
- CPI-613
- Where
- 4 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Cornerstone Pharmaceuticals
Gastrointestinal Tumor, Solid Tumor
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, non-randomized Phase I clinical study with dose-escalation and expansion cohorts, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy…
- Trial name
- NCT07678970
- Testing
- SI-B036
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.